Effects of Allergen Inhalation on Adenosine Receptor Expression in Sputum and Peripheral Blood

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2007 by Groningen Research Institute for Asthma and COPD.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Groningen Research Institute for Asthma and COPD
ClinicalTrials.gov Identifier:
NCT00116311
First received: June 28, 2005
Last updated: March 20, 2007
Last verified: March 2007

June 28, 2005
March 20, 2007
July 2005
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00116311 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Effects of Allergen Inhalation on Adenosine Receptor Expression in Sputum and Peripheral Blood
Effects of Allergen Inhalation on Adenosine Receptor Expression and Mast Cell Activation in Peripheral Blood and Sputum of Asthmatics and Healthy Subjects

The purpose of this study is to determine whether asthmatics have different adenosine receptor expression profiles than healthy controls. We hypothesize that asthmatics will have increased adenosine receptor expression versus control subjects.

We also want to study the effects of allergen inhalation on adenosine receptor expression in asthmatics. We believe that adenosine receptor expression will be upregulated after allergen inhalation.

Both hypotheses are being tested in sputum and peripheral blood.

Not Provided
Observational
Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Not Provided
Not Provided
  • Asthma
  • Healthy
  • Behavioral: allergen inhalation
  • Behavioral: withdrawal of medication
  • Procedure: sputum induction
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
20
February 2007
Not Provided

Asthmatic Subjects - Inclusion Criteria:

  • Clinical diagnosis of asthma
  • Steroid naive or subjects not using their inhaled steroids for the last 4 weeks, short-acting beta-agonist for rescue medication
  • FEV1 > 70% of predicted
  • Positive skin prick test for house dust mite, cat or grass pollen
  • PC20 methacholine or histamine < 8 mg/ml

Asthmatic Subjects - Exclusion Criteria:

  • Use of systemic steroids in the previous 6 weeks
  • Asthma exacerbations in the previous 6 weeks
  • Current or ex-smokers with ≥ 10 pack-years (≥ 2 pipe pack-years), ex smokers who stopped less than 1 year ago

Healthy Subjects - Inclusion Criteria:

  • No airway complaints
  • FEV1 > 90% of predicted
  • Negative skin prick test
  • PC20 methacholine or histamine > 8 mg/ml

Healthy Subjects - Exclusion Criteria:

  • Use of steroids in the previous 6 weeks
  • Current or ex-smokers with ≥ 10 pack-years (≥ 2 pipe pack-years), ex smokers who stopped less than 1 year ago
Both
18 Years to 50 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Netherlands
 
NCT00116311
METc2004-253
No
Not Provided
Groningen Research Institute for Asthma and COPD
Not Provided
Principal Investigator: Dirkje S Postma, prof. MD PhD University Medical Center Groningen, Department of Pulmonology, hanzeplein 1, 9713 GZ Groningen, The Netherlands
Groningen Research Institute for Asthma and COPD
March 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP